Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeparOcto neoadjuvant high-risk early breast cancer trial
2014-000619-14Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Jun 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, paclitaxel, cyclophosphamide, carboplatin, trastuzumab and 2 more in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Pathological complete response. Started Jun 2014; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-000619-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000619-14.